子宫静脉内平滑肌瘤病的诊治进展

doi:10.12280/gjfckx.20211159

摘要/Abstract

摘要：

子宫静脉内平滑肌瘤病（intravenous leiomyomatosis，IVL）是一种罕见的疾病，可沿血管生长，延伸到下腔静脉，甚至心脏。目前对其发病机制尚有争议，多数学者考虑其起源于子宫肌瘤直接侵入子宫肌层静脉并沿血管腔扩散所致。子宫IVL好发于40~50岁有生育史的女性，早期临床表现不典型，如累及下腔静脉或右心时，可出现腹水、肝脾肿大、呼吸困难、心力衰竭，严重者甚至猝死。手术是目前首选的治疗方法，但具体的手术方案尚无统一共识。该病复发率高，术后需长期严密随访。综述子宫IVL的发病机制及高危因素、临床及影像学表现、诊断与鉴别诊断、治疗、预后及随访，以期为该病的诊疗提供参考。

关键词: 静脉内平滑肌瘤病, 平滑肌瘤病, 子宫, 诊断, 治疗, 预后

Abstract:

Uterine intravenous leiomyomatosis (IVL) is a rare disease. The tumor typically grows along vascular vessels and can extend to the inferior vena cava, even to the heart. The pathogenesis remains still controversial at present. Most scholars are inclined to consider that the leiomyoma directly invades into myometrial veins and spreads along the vascular lumen. Uterine IVL usually occurs in 40 to 50 years old women with a reproductive history. The clinical manifestations in the early stages are not typical. If the lesion involves the inferior vena cava or right heart, it can cause ascites, hepatosplenomegaly, dyspnea, heart failure, and even sudden death in severe cases. Surgery is currently the preferred treatment method, but there is no consensus on the specific surgical plan. The recurrence rate of the disease is high, and long-term and close follow-up is required after the operation. The pathogenesis, high risk fators, clinical and imaging manifestations, diagnosis and differential diagnosis, treatment and prognosis of uterine IVL are reviewed, in order to provide references for the diagnosis and treatment of the disease in the future.

Key words: Intravenous leiomyomatosis, Leiomyomatosis, Uterus, Diagnosis, Therapy, Prognosis

许阡, 王欣. 子宫静脉内平滑肌瘤病的诊治进展[J]. 国际妇产科学杂志, 2022, 49(6): 616-620.

XU Qian, WANG Xin. Research Progress in Diagnosis and Treatment of Uterine Intravenous Leiomyomatosis[J]. Journal of International Obstetrics and Gynecology, 2022, 49(6): 616-620.

参考文献 34

[1]	Han Y, Chung YJ, Shin I, et al. Intravenous leiomyomatosis misdiagnosed with large thrombosis in inferior vena cava[J]. Taiwan J Obstet Gynecol, 2021, 60(2):367-369. doi: 10.1016/j.tjog.2021.01.019. doi: 10.1016/j.tjog.2021.01.019 pmid: 33678345
[2]	Lian C, Yin S, Qiu J, et al. Experience in the diagnosis and treatment of intravenous leiomyomatosis involving the inferior vena cava and/or right cardiac chambers[J]. J Vasc Surg Venous Lymphat Disord, 2021, 9(2):452-460. doi: 10.1016/j.jvsv.2020.05.011. doi: 10.1016/j.jvsv.2020.05.011 pmid: 32464287
[3]	Masood I, Duran C, Malik K, et al. Uterineintravenous leiomyomatosis with cardiac involvement[J]. Radiol Case Rep, 2020, 15(8):1389-1393. doi: 10.1016/j.radcr.2020.05.053. doi: 10.1016/j.radcr.2020.05.053
[4]	Sun R, Guan H, Li H, et al. Computed tomography evaluation of extensive intravenous angioleiomyoma: a case report[J]. BMC Med Imaging, 2020, 20(1):13. doi: 10.1186/s12880-020-0417-2. doi: 10.1186/s12880-020-0417-2 pmid: 32028907
[5]	Knauer E. Beitrag zur Anatomie der Uterusmyome[J]. Beur Geburtshilfe, 1903, 1:695.
[6]	Fang H, You Y, Cai F, et al. Intravenous leiomyomatosis of the subclavian vein[J]. J Vasc Surg Venous Lymphat Disord, 2017, 5(2):254-256. doi: 10.1016/j.jvsv.2016.03.008. doi: S2213-333X(16)30022-1 pmid: 28214494
[7]	Su Q, Zhang X, Zhang H, et al. Intravenous Leiomyomatosis of the Uterus: A Retrospective Single-Center Study in 14 Cases[J]. Biomed Res Int, 2020, 2020:9758302. doi: 10.1155/2020/9758302. doi: 10.1155/2020/9758302
[8]	Miro A, Coppola Bottazzi E, Vanella S, et al. Intravascular leiomyomatosis with intracardiac extension: a toraco-abdominal approach[J]. J Surg Case Rep, 2021, 2021(6): rjab249. doi: 10.1093/jscr/rjab249. doi: 10.1093/jscr/rjab249
[9]	Yu X, Fu J, Cao T, et al. Clinicopathologic features and clinical outcomes of intravenous leiomyomatosis of the uterus: A case series[J]. Medicine(Baltimore), 2021, 100(1):e24228. doi: 10.1097/MD.0000000000024228. doi: 10.1097/MD.0000000000024228
[10]	Deng Y, Song B. Three Case Reports of Intravenous Leiomyomatosis with Intracardiac Extensions[J]. Thorac Cardiovasc Surg Rep, 2020, 9(1):e40-e43. doi: 10.1055/s-0040-1715183. doi: 10.1055/s-0040-1715183
[11]	Zhang X, Wu L, Xu R, et al. Identification of the molecular relationship between intravenous leiomyomatosis and uterine myoma using RNA sequencing[J]. Sci Rep, 2019, 9(1):1442. doi: 10.1038/s41598-018-37452-3. doi: 10.1038/s41598-018-37452-3 pmid: 30723247
[12]	Lee E, LaBounty T, Romano M, et al. Case of the Season: Intravenous Leiomyomatosis: a Rare Cause of Intracardiac Mass[J]. Semin Roentgenol, 2020, 55(3):226-229. doi: 10.1053/j.ro.2020.06.009. doi: S0037-198X(20)30034-1 pmid: 32859339
[13]	Tang L, Lu B. Intravenous leiomyomatosis of the uterus: A clinicopathologic analysis of 13 cases with an emphasis on histogenesis[J]. Pathol Res Pract, 2018, 214(6):871-875. doi: 10.1016/j.prp.2018.04.011. doi: S0344-0338(18)30068-2 pmid: 29699902
[14]	王蛟, 张宁宁, 杨清. 子宫静脉内平滑肌瘤病48例临床分析[J]. 国际妇产科学杂志, 2020, 47(5):554-557. doi: 10.3969/j.issn.1674-1870.2020.05.016. doi: 10.3969/j.issn.1674-1870.2020.05.016
[15]	Ma G, Miao Q, Liu X, et al. Different surgical strategies of patients with intravenous leiomyomatosis[J]. Medicine(Baltimore), 2016, 95(37):e4902. doi: 10.1097/MD.0000000000004902. doi: 10.1097/MD.0000000000004902
[16]	Stilidi I, Paianidi J, Bokhian V, et al. Intracardiac intravenous leiomyomatosis: diagnosis and management[J]. Int J Gynecol Cancer, 2020, 30(8):1243-1247. doi: 10.1136/ijgc-2020-001614. doi: 10.1136/ijgc-2020-001614 pmid: 32641391
[17]	Marrone G, Crinò F, Morsolini M, et al. Multidisciplinary approach in the management of uterine intravenous leiomyomatosis with intracardiac extension: case report and review of literature[J]. J Radiol Case Rep, 2019, 13(7):1-13. doi: 10.3941/jrcr.v13i7.3607. doi: 10.3941/jrcr.v13i7.3607
[18]	Schultz KL, Quinn SM, Miller AH, et al. Point of care ultrasound facilitated diagnosis of right ventricular mass as the etiology of syncope; A case report of intravenous leiomyomatosis[J]. Radiol Case Rep, 2021, 16(6):1288-1293. doi: 10.1016/j.radcr.2021.02.062. doi: 10.1016/j.radcr.2021.02.062
[19]	Luo X, Li R, Li Z. Combined transthoracic echocardiography and contrast-enhanced ultrasonography to trace intravenous leiomyomatosis with intracardiac extension[J]. Echocardiography, 2019, 36(8):1573-1576. doi: 10.1111/echo.14424. doi: 10.1111/echo.14424 pmid: 31260144
[20]	Mathey MP, Duc C, Huber D. Intravenous leiomyomatosis: Case series and review of the literature[J]. Int J Surg Case Rep, 2021, 85:106257. doi: 10.1016/j.ijscr.2021.106257. doi: 10.1016/j.ijscr.2021.106257
[21]	Park SY, Yeo IH, Kim YJ, et al. Obstruction of the Hepatic Venous Flow Caused by Intravenous Leiomyomatosis[J]. Medicina(Kaunas), 2020, 56(12):696. doi: 10.3390/medicina56120696. doi: 10.3390/medicina56120696
[22]	Van Maercke J, Van Rompuy AS, Poppe W, et al. Intravascular Leiomyomatosis as a Rare Cause of Nonthrombotic Pulmonary Embolism[J]. Case Rep Vasc Med, 2020, 2020:6084061. doi: 10.1155/2020/6084061. doi: 10.1155/2020/6084061
[23]	Wang H, Nie P, Chen B, et al. Contrast-enhanced CT findings of intravenous leiomyomatosis[J]. Clin Radiol, 2018, 73(5):503.e1-503.e6. doi: 10.1016/j.crad.2017.12.016. doi: 10.1016/j.crad.2017.12.016
[24]	Lu B, Liu Q, Tang L, et al. Intravenous leiomyomatosis: molecular analysis of 17 cases[J]. Pathology, 2020, 52(2):213-217. doi: 10.1016/j.pathol.2019.10.009. doi: 10.1016/j.pathol.2019.10.009
[25]	Ordulu Z, Chai H, Peng G, et al. Molecular and clinicopathologic characterization of intravenous leiomyomatosis[J]. Mod Pathol, 2020, 33(9):1844-1860. doi: 10.1038/s41379-020-0546-8. doi: 10.1038/s41379-020-0546-8
[26]	Kommoss F, Ebel T, Drusenheimer J, et al. Intravenous leiomyomatosis[J]. Pathologe, 2019, 40(1):80-84. doi: 10.1007/s00292-019-0566-7. doi: 10.1007/s00292-019-0566-7 pmid: 30680436
[27]	Luo G, Pan H, Bi J, et al. Surgical treatment of intravenous leiomyomatosis involving the right heart: a case series[J]. J Int Med Res, 2019, 47(7):3465-3474. doi: 10.1177/0300060519858021. doi: 10.1177/0300060519858021 pmid: 31280644
[28]	Li H, Xu J, Lin Q, et al. Surgical treatment strategies for extra-pelvic intravenous leiomyomatosis[J]. Orphanet J Rare Dis, 2020, 15(1):153. doi: 10.1186/s13023-020-01394-9. doi: 10.1186/s13023-020-01394-9 pmid: 32546179
[29]	Akinseye OA, Nayyar M, Das P. Uterine intravenous leiomyomatosis with femoral vein, intracaval, intracardiac and pulmonary artery extension[J]. Future Cardiol, 2020, 16(1):27-32. doi: 10.2217/fca-2019-0002. doi: 10.2217/fca-2019-0002 pmid: 31766884
[30]	Deng Y, Dong S, Song B. Surgical Strategy for Intravenous Cardiac Leiomyomatosis[J]. Heart Lung Circ, 2021, 30(2):240-246. doi: 10.1016/j.hlc.2020.07.006. doi: 10.1016/j.hlc.2020.07.006 pmid: 32830033
[31]	Low HY, Zhao Y, Huang KS, et al. Intravenous leiomyomatosis of the uterus: A clinicopathological analysis of nine cases and literature review[J]. Taiwan J Obstet Gynecol, 2017, 56(3):362-365. doi: 10.1016/j.tjog.2017.04.017. doi: 10.1016/j.tjog.2017.04.017
[32]	Li B, Chen X, Chu YD, et al. Intracardiac leiomyomatosis: a comprehensive analysis of 194 cases[J]. Interact Cardiovasc Thorac Surg, 2013, 17(1):132-138. doi: 10.1093/icvts/ivt117. doi: 10.1093/icvts/ivt117
[33]	Zhang G, Feng F, Wang W, et al. Rapamycin (sirolimus) in treatment of recurrent intravenous leiomyomatosis: a case report[J]. BJOG, 2020, 127(6):768-771. doi: 10.1111/1471-0528.16156. doi: 10.1111/1471-0528.16156
[34]	Declas E, Lucot JP. Extra uterine leiomyomatosis: Review of the literature[J]. Gynecol Obstet Fertil Senol, 2019, 47(7/8):582-590. doi: 10.1016/j.gofs.2019.06.010. doi: 10.1016/j.gofs.2019.06.010